To the Editor: According to the Food and Drug Administration,trovafloxacin, a broad-spectrum quinolone antibiotic, has beenassociated with more than 100 cases of hepatic toxicity. Fourteenof these cases involved acute liver failure, with transplantationrequired in four patients; five patients died of liver disease.More than 300,000 prescriptions for trovafloxacin were writtenmonthly in the United States before use of the drug was limitedto certain serious infections in an inpatient setting.
There have been a few reports of hepatic toxicity associatedwith the use of quinolones1,2,3 but to our knowledge no publishedreports of toxicity associated with . . . [Full Text of this Article]
References
This article has been cited by other articles:
Shaw, P. J., Ganey, P. E., Roth, R. A.
(2009). Tumor Necrosis Factor{alpha} Is a Proximal Mediator of Synergistic Hepatotoxicity from Trovafloxacin/Lipopolysaccharide Coexposure. J. Pharmacol. Exp. Ther.
328: 62-68
[Abstract][Full Text]
Barequet, I. S., Denton, P., Osterhout, G. J., Tuli, S., O'Brien, T. P.
(2004). Treatment of Experimental Bacterial Keratitis With Topical Trovafloxacin. Arch Ophthalmol
122: 65-69
[Abstract][Full Text]
Jaruga, B., Hong, F., Sun, R., Radaeva, S., Gao, B.
(2003). Crucial Role of IL-4/STAT6 in T Cell-Mediated Hepatitis: Up-Regulating Eotaxins and IL-5 and Recruiting Leukocytes. J. Immunol.
171: 3233-3244
[Abstract][Full Text]